Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Frontiers in Oncology 9 (2019) 839, 1-7
- Event
-
Veröffentlichung
- (where)
-
Münster
- (who)
-
Universitäts- und Landesbibliothek Münster
- (when)
-
2020
- Creator
- DOI
-
10.3389/fonc.2019.00839
- URN
-
urn:nbn:de:hbz:6-59029480356
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:43 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schütte, Judith
- Reusch, Julia
- Khandanpour, Cyrus
- Eisfeld, Christine
- Universitäts- und Landesbibliothek Münster
Time of origin
- 2020
Other Objects (12)
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Developing targeted therapies for pediatric PFA ependymoma
Prostate cancer stem cells: Clinical aspects and targeted therapies
Mouse models and targeted therapies for RAS-driven tumours
Moment Targeted Structural Innovations
Increasing oncoselectivity of virotherapy: Receptor targeted viruses against CD30-positive malignancies
Targeted therapies for the treatment of triple-negative breast cancer
Network meta-analysis for the integrated evaluation of targeted therapies
Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
Molecular mechanisms of PI3K/mTOR-targeted therapies in hepatocellular carcinoma
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Developing targeted therapies for pediatric PFA ependymoma
Prostate cancer stem cells: Clinical aspects and targeted therapies
Mouse models and targeted therapies for RAS-driven tumours
Moment Targeted Structural Innovations
Increasing oncoselectivity of virotherapy: Receptor targeted viruses against CD30-positive malignancies
Targeted therapies for the treatment of triple-negative breast cancer
Network meta-analysis for the integrated evaluation of targeted therapies
Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
Molecular mechanisms of PI3K/mTOR-targeted therapies in hepatocellular carcinoma
Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Developing targeted therapies for pediatric PFA ependymoma
Prostate cancer stem cells: Clinical aspects and targeted therapies
Mouse models and targeted therapies for RAS-driven tumours
Moment Targeted Structural Innovations
Increasing oncoselectivity of virotherapy: Receptor targeted viruses against CD30-positive malignancies
Targeted therapies for the treatment of triple-negative breast cancer
Network meta-analysis for the integrated evaluation of targeted therapies
Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis
Molecular mechanisms of PI3K/mTOR-targeted therapies in hepatocellular carcinoma